Recursion Pharmaceuticals, Inc. (RXRX)
4.12
+0.05
(+1.23%)
USD |
NASDAQ |
Oct 02, 16:00
4.12
0.00 (0.00%)
After-Hours: 20:00
Recursion Pharmaceuticals Net Income (Quarterly) : -131.00M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -131.00M |
| March 31, 2026 | -117.50M |
| December 31, 2025 | -108.12M |
| September 30, 2025 | -162.25M |
| June 30, 2025 | -171.90M |
| March 31, 2025 | -202.49M |
| December 31, 2024 | -178.91M |
| September 30, 2024 | -95.84M |
| June 30, 2024 | -97.54M |
| March 31, 2024 | -91.37M |
| December 31, 2023 | -93.00M |
| September 30, 2023 | -93.02M |
| June 30, 2023 | -76.73M |
| Date | Value |
|---|---|
| March 31, 2023 | -65.33M |
| December 31, 2022 | -57.49M |
| September 30, 2022 | -60.44M |
| June 30, 2022 | -65.56M |
| March 31, 2022 | -55.98M |
| December 31, 2021 | -64.93M |
| September 30, 2021 | -47.43M |
| June 30, 2021 | -43.40M |
| March 31, 2021 | -30.72M |
| December 31, 2020 | -25.77M |
| September 30, 2020 | -23.87M |
| June 30, 2020 | -18.94M |
| March 31, 2020 | -18.42M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Editas Medicine, Inc. | -18.23M |
| Amgen, Inc. | 2.375B |
| Halozyme Therapeutics, Inc. | 229.91M |
| Novavax, Inc. | -53.39M |
| AVITA Medical, Inc. | -7.663M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 7.67M |
| Total Expenses (Quarterly) | 138.68M |
| EPS Diluted (Quarterly) | -0.246 |
| Enterprise Value | 1.716B |
| Gross Profit Margin (Quarterly) | -202.4% |
| Profit Margin (Quarterly) | -1.71K% |
| Earnings Yield | -25.15% |
| Normalized Earnings Yield | -25.15 |